Latest News

Attune Ensemble™ OTC, a First of its Kind Cancer Well-Being App, is Now Available for Free to Spanish-Speaking Patients

June 2022

Designed to help patients cope with the emotional symptoms of cancer, Blue Note is excited to bring the Hispanic and Latino community a new cancer-specific wellness app.

Read more →

OncoHealth and Blue Note Therapeutics Partner to Provide a Digital Therapeutic for Treating Cancer-related Anxiety and Depression Symptoms

May 2022

Blue Note and OncoHealth have joined to provide patients coping with cancer oncology-specific mental health care.

Read more →

Blue Note Therapeutics and Bixink Enter Licensing Agreement for attune™ and DreAMLand™, Prescription Digital Therapeutics for Mental Well-Being in Cancer Patients

May 2022

In support of expanding access to cancer-specific digital therapeutics, Blue Note has entered into an exclusive licensing agreement with Bixink for the commercialization of attune™ and DreAMLand™ in South Korea.

Read more →

New Study Finds Cancer-Related Anxiety and Depression are Costing Medicare $5B Annually

March 2022

Blue Note Therapeutics announces findings of new study highlighting the financial impacts of cancer-related anxiety and depression in Medicare beneficiaries.

Read more →

Blue Note Therapeutics to Present Health Economic Data at NCCN 2022 Annual Conference

March 2022

Blue Note Therapeutics will share new findings on the incremental healthcare costs of anxiety and depression in Medicare patients living with cancer. This is the largest and most comprehensive assessment of its kind.

Read more →

Curebase and Blue Note Therapeutics Collaborate on Home-based Clinical Trial of Prescription Digital Therapeutics to Help People with Cancer Manage Their Health

March 2022

Blue Note Therapeutics and Curebase announce launch of a new, fully virtual clinical trial to maximize recruitment efforts with patients experiencing cancer-related distress.

Read more →

Blue Note to Participate in New Pink Paradigm Summit

March 2022

Joined by patient advisor, Stacey Tinianov, Blue Note will take stage at the inaugural New Pink Paradigm Summit to talk with breast cancer leaders and advocates about the emotional challenges that often come with cancer.

Read more →

Blue Note Therapeutics Sponsors the APOS Jimmie Holland Lifetime Achievement Award

March 2022

Blue Note Therapeutics is excited to announce co-sponsorship of the 2022 Jimmie Holland Lifetime Achievement Award, the highest honor conferred by the American Psychosocial Oncology Society.

Read more →

Blue Note Therapeutics Enters Licensing Agreement with University of Sydney for ConquerFear, a Cancer Survivorship Intervention

February 2022

In support of providing solutions to patients beyond active cancer treatment, Blue Note Therapeutics has entered into an exclusive licensing agreement for ConquerFear, an intervention to teach patients ways to cope with fear of cancer recurrence.

Read more →

Blue Note Therapeutics Receives Breakthrough Device Designation for Prescription-only Digital Therapeutic for Acute Myeloid Leukemia

January 2022

Blue Note Therapeutics receives U.S. FDA Breakthrough Device Designation for BNT200, a first-of-its kind prescription-only digital therapeutic to treat the anxiety and depressive symptoms in patients with AML.

Read more →